AI entity
IonQ is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 11-day window averages about 1.3 stories each week. They are less corroborated than the beat average, carrying 2.5 original sources each against 2.6 for the same window.
Last mentioned: Aug 9, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
IonQ is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 11-day window averages about 1.3 stories each week. They are less corroborated than the beat average, carrying 2.5 original sources each against 2.6 for the same window. Coverage clusters in ai-models, which accounts for 1 of those 2, with the remainder spread across 1 other category. The 6 average consequence score is below the beat benchmark of 6.5 in the same window. We currently track 2 AI stories that mention Eli Lilly, published between March 4, 2026 and March 14, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 375 AI stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Eli Lilly. Shared-story counts are live from our verified record — not editorial picks.
Seeking Alpha's latest quantitative analysis of large-cap stocks highlights a widening performance gap driven by AI integration across healthcare, technology, and communication services. The data suggests that companies successfully operationalizing machine learning are securing superior quant scores and market premiums.
As the AI sector matures in 2026, investors are pivoting toward companies that successfully integrate generative AI and machine learning into specialized verticals like healthcare and voice automation. Key players including Eli Lilly and SoundHound AI are demonstrating how AI-powered drug discovery and conversational interfaces are translating into significant revenue growth and market leadership.
Eli Lilly is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
